Second-line treatments for pneumocystis pneumonia in immunocompromised patients
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed or likely Pneumocystis pneumonia (a lung infection).
- You could not take the standard antibiotic (trimethoprim-sulfamethoxazole) because of allergy, side effects, or it didn’t work.
- You have a weakened immune system from HIV, organ transplant, cancer, or certain medications.
- You cannot have a severe allergy to any of the study drugs (clindamycin, primaquine, atovaquone, or pentamidine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This study compares two different lengths of steroid treatment for people with severe Pneumocystis pneumonia (a serious lung infection). If you have improved enough by day 10 to breathe without oxygen, the study will see if stopping steroids sooner is as safe and effective as continuing them.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
This trial tests a new inhaled medicine (caspofungin) added to standard treatment for Pneumocystis pneumonia, a serious lung infection. It may help fight the infection more effectively while you are already receiving oxygen and standard antibiotics.
This study compares a lower dose versus the standard dose of the antibiotic TMP-SMX (Bactrim) to prevent a type of lung infection (Pneumocystis pneumonia) after a kidney transplant. If you are eligible, you will receive either a lower or standard dose to see which works just as well with fewer side effects.
Hear when a new Pneumocystis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.